Ikarian Capital’s MBX Biosciences MBX Stock Holding History

Ikarian Capital’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200,000	Closed	-$3.5M	–	230
2025 Q3	$3.5M	Buy	+200,000	New	+$2.67M	0.35%	75

Other funds holding MBX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ikarian Capital's MBX Position: Q4 2025 in Review

Ikarian Capital sold out of MBX Biosciences (MBX) in Q4 2025, closing a stake of 48,071 shares — an estimated $841K sold.

Ikarian Capital first reported a position in MBX in Q3 2025 and held it in 1 quarter. The position peaked at $841K in Q3 2025. 138 funds tracked by Wall St. Rank hold MBX as of Q4 2025.

Ikarian Capital reported no remaining MBX Biosciences position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 48,071 MBX Biosciences shares in Q4 2025, an estimated $841K.
Ikarian Capital first reported a position in MBX Biosciences in Q3 2025 and held it in 1 quarter.
Ikarian Capital's MBX Biosciences position peaked at $841K in Q3 2025.
138 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.